Table IV.
SSTR2 and SSTR5 expression and clinicopathological characteristics.
| Clinicopathological characteristic | No. | SSTR2+ cases n (%) | χ2 value | P-value | STR5+ cases n (%) | χ2 value | P-value |
|---|---|---|---|---|---|---|---|
| Tumor location | |||||||
| Stomach + duodenum | 12 | 8 (66.66) | 1.252 | 0.869 | 3(25) | Non-valid | |
| Small intestine | 10 | 10(100) | 5(50) | ||||
| Appendix | 6 | 6(100) | 1 (16.7) | ||||
| Colon | 24 | 12(50) | 8 (33.33) | ||||
| Hepatic metastases | 19 | 11 (57.9) | 3 (15.8) | ||||
| Tumor grade | |||||||
| G1 | 28 | 27 (96.4) | 30.27 | <0.0001 | 10 (35.7) | 3.361 | 0.1863 |
| G2 | 21 | 15 (71.4) | 7 (33.3) | ||||
| G3 | 22 | 5 (22.7) | 3 (13.6) | ||||
| Tumor type | |||||||
| NET | 52 | 39(75) | 6.174 | 0.0130 | 17 (32.7) | 4.068 | 0.0437 |
| NEC+MiNEN+AGCC | 19 | 8 (42.10) | 3 (11.53) | ||||
| Tumor stage | |||||||
| I+II | 16 | 16(100) | 3.253 | 0.0011 | 7 (43.8) | 2.115 | 0.1459 |
| III+IV | 45 | 25 (55.6) | 11 (24.4) |
SSTR, somatostatin receptor; G, grade; NET, neuroendocrine tumor; NEC, neuroendocrine carcinoma; MiNEN, mixed neuroendocrine non-neuroendocrine neoplasm; AGCC, adenocarcinoma ex-goblet cell carcinoid.